A neurological tug-of-war is taking place between patients, physicians, and the FDA. The agency (or its committees) keeps rejecting Alzheimer’s therapies (for good reason), but patients and physicians keep sounding the alarm (also for good reason), claiming that any therapy that poses even a modest benefit is sorely needed for a condition that affects millions….

With medicinal cannabis earning legalization in several states and across the United States, research gaps are beginning to close. But this week, we’re bringing bad news for proponents of cannabinoids as analgesics. You’ll also find research pointing to racial disparities in dementia diagnoses, a simple supplement that may improve age-related defects, research into a cancer…

Scientists have long thought that schizophrenia may be associated with the zoonotic parasite Toxoplasma gondii. While evidence for that hypothesis remains elusive, this week we’re bringing you a study that’s found evidence of bloodstream Bartonella infection in patients with schizophrenia—which suggests cats and schizophrenia may really be linked after all. In this issue, you’ll also…

Conversion disorder leaves patients abruptly unable to walk, talk, or see, and its causes have stumped scientists for years. But this week, we’re bringing you new findings that may have cracked this mystery. In this issue, you’ll also find a study that suggests a Parkinson’s diagnosis may be a simple skin swab away, research into…

It seems like all the news surrounding CRISPR gene-editing tools focuses on designer babies and the possible ecological harm caused by modifying animals. But, as scientists and doctors know, the tool has less fear-inducing applications as well. This week, a study suggests that temporarily repressing a gene involved in sensing pain could be a safer…